CoChat

The DOI matches its Crossref record; 353 of the 372 references it cites were found in a registry or an index; 83 of the 236 sources its claims cite were checked for support.

Current State of Therapeutics for HTLV-1

Open access

Abstract

Human T cell leukaemia virus type-1 (HTLV-1) is an oncogenic retrovirus that causes lifelong infection in ~5–10 million individuals globally. It is endemic to certain First Nations populations of Northern and Central Australia, Japan, South and Central America, Africa, and the Caribbean region. HTLV-1 preferentially infects CD4+ T cells and remains in a state of reduced transcription, often being asymptomatic in the beginning of infection, with symptoms developing later in life. HTLV-1 infection is implicated in the development of adult T cell leukaemia/lymphoma (ATL) and HTLV-1-associated myelopathies (HAM), amongst other immune-related disorders. With no preventive or curative interventions, infected individuals have limited treatment options, most of which manage symptoms. The clinical burden and lack of treatment options directs the need for alternative treatment strategies for HTLV-1 infection. Recent advances have been made in the development of RNA-based antiviral therapeutics for Human Immunodeficiency Virus Type-1 (HIV-1), an analogous retrovirus that shares modes of transmission with HTLV-1. This review highlights past and ongoing efforts in the development of HTLV-1 therapeutics and vaccines, with a focus on the potential for gene therapy as a new treatment modality in light of its successes in HIV-1, as well as animal models that may help the advancement of novel antiviral and anticancer interventions.

Overview

CoChat Summary

## TL;DR

This review argues that HTLV-1 still lacks approved curative or preventive therapy, and that current treatment is largely symptomatic or repurposed from HIV and oncology drugs. It highlights gene-targeting approaches, especially RNAi and gene editing, plus BLV vaccination as the most promising directions for future HTLV-1 interventions.

## Key findings

  • HTLV-1 causes lifelong infection in an estimated ~5–10 million people globally, with global prevalence estimates ranging from 3 to 30 million cases.
  • The lifetime risk of ATL in carriers is estimated at 1–5%, and the risk of HAM at about 3%; among carriers, the risk of early neurological disorders can be as high as 24%.
  • Existing ART has limited impact because it cannot eliminate HTLV-1 reservoirs driven by clonal expansion; for example, AZT + lamivudine in a randomized double-blind placebo-controlled HAM trial produced no significant reduction in PVL or clinical measures after 24 weeks.
  • In HAM, a multicentre randomized phase III mogamulizumab study found no significant difference in the primary or secondary motor endpoints at the end of the double-blind period, but it did significantly reduce PVL and CSF CXCL10/neopterin; earlier phase I/IIa data in 21 patients reported improved motor ability in 32% and reduced spasticity in 79%.
  • The BLV vaccine is presented as a model for HTLV-1 vaccination: in Argentina it conferred immunity in 28 of 29 cows over 4 years and was reported as safe and effective.

## Methods

  • Narrative review of past and ongoing HTLV-1 therapeutics and vaccines, with emphasis on similarities to HIV-1 and on gene therapy/RNA-based approaches.
  • Synthesizes evidence from cell models, animal models (mice, rabbits, non-human primates, humanized mice), and clinical studies/trials in ATL and HAM.
  • Main analysis is comparative and descriptive, evaluating how different therapeutic strategies affect PVL, viral gene expression, tumor burden, and clinical outcomes.

## Limitations

  • The paper states that there are no preventive or curative interventions for HTLV-1 and that there are no approved HTLV-1-specific inhibitors or antiviral ASOs.
  • For HAM and other HTLV-1-associated inflammatory diseases, the paper notes that studies are often observational, with small cohorts and geographic constraints.
  • Evident from the text: much of the evidence comes from preclinical models, and the review itself notes major gaps in in vivo/in vitro HTLV-1 studies, efficient delivery for gene therapies, and clinical translation of RNAi/gene-editing approaches.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/v16101616

Cites

353 of 353 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Worldwide distribution of HTLV-1 infection. The map specifies the prevalence by region. Created with mapchart.net (2022).
Figure 1 Worldwide distribution of HTLV-1 infection. The map specifies the prevalence by region. Created with mapchart.net (2022).CC BY · PubMed Central
Figure 2 The genomic structure of HTLV-1. The 3′ region is described as the pX region. Tax, rex, and hbz are spliced. Created in BioRender.
Figure 2 The genomic structure of HTLV-1. The 3′ region is described as the pX region. Tax, rex, and hbz are spliced. Created in BioRender.CC BY · PubMed Central
Figure 3 The HTLV-1 life cycle in a cell. The virus fuses into the host cell, CD4+/CD8+ T cells, through interaction with cell surface receptors. The viral core is transported into the cytoplasm where it is reverse transcribed into a double-stranded DNA. This is then transported into the nucleus and integrated into the host genome. The viral proteins are transcribed and translated by the host cell machinery and become infectious after undergoing viral budding. Created in BioRender.
Figure 3 The HTLV-1 life cycle in a cell. The virus fuses into the host cell, CD4+/CD8+ T cells, through interaction with cell surface receptors. The viral core is transported into the cytoplasm where it is reverse transcribed into a double-stranded DNA. This is then transported into the nucleus and integrated into the host genome. The viral proteins are transcribed and translated by the host cell machinery and become infectious after undergoing viral budding. Created in BioRender.CC BY · PubMed Central
Figure 4 Disease progression of HTLV-1 and the rates of infection. HTLV-1 mostly presents in infected patients as a lifelong subtle immune dysfunction without a defined associated disease, with a broadly estimated 10–30% of populations developing symptomatic HTLV-1-associated disease. There is, however, a broad spectrum of diseases that are reported with infection other than HAM and ATL. Understanding the determinants of if, when, and what disease afflicts infected individuals needs to be further addressed. Created in BioRender.
Figure 4 Disease progression of HTLV-1 and the rates of infection. HTLV-1 mostly presents in infected patients as a lifelong subtle immune dysfunction without a defined associated disease, with a broadly estimated 10–30% of populations developing symptomatic HTLV-1-associated disease. There is, however, a broad spectrum of diseases that are reported with infection other than HAM and ATL. Understanding the determinants of if, when, and what disease afflicts infected individuals needs to be further addressed. Created in BioRender.CC BY · PubMed Central
Figure 5 Mechanisms of siRNA-induced gene silencing. Both RNAi pathways can exert genetic repression by viral and non-viral mechanisms of delivery. PTGS mostly occurs in the cytoplasm as the RISC machinery initiates specific mRNA cleavage. TGS is localised to the nucleus and is mediated by the RITS complex, acting through repressive epigenetic modifications. Ago1, Argonaute 1; Ago2, Argonaute 2; shRNA, short hairpin RNA; RISC, RNA-induced silencing complex; RITS, RNA-induced transcriptional silencing complex; TRBP, transactivating response (TAR) RNA-binding protein; TNRC6, trinucleotide repeat containing 6 protein faily. Created in BioRender.
Figure 5 Mechanisms of siRNA-induced gene silencing. Both RNAi pathways can exert genetic repression by viral and non-viral mechanisms of delivery. PTGS mostly occurs in the cytoplasm as the RISC machinery initiates specific mRNA cleavage. TGS is localised to the nucleus and is mediated by the RITS complex, acting through repressive epigenetic modifications. Ago1, Argonaute 1; Ago2, Argonaute 2; shRNA, short hairpin RNA; RISC, RNA-induced silencing complex; RITS, RNA-induced transcriptional silencing complex; TRBP, transactivating response (TAR) RNA-binding protein; TNRC6, trinucleotide repeat containing 6 protein faily. Created in BioRender.CC BY · PubMed Central
Figure 6 Routes of administration for nanoparticle delivery of RNAi therapeutics. (A) Chemical modifications, siRNA conjugations, and nanoparticle formulations can be used to improve the outcomes of delivery. Nanoparticle formulation helps to facilitate cell entry and endosomal escape to yield enhanced epigenetic silencing. (B) The different routes of administration for nanoparticle formulation. Created in BioRender.
Figure 6 Routes of administration for nanoparticle delivery of RNAi therapeutics. (A) Chemical modifications, siRNA conjugations, and nanoparticle formulations can be used to improve the outcomes of delivery. Nanoparticle formulation helps to facilitate cell entry and endosomal escape to yield enhanced epigenetic silencing. (B) The different routes of administration for nanoparticle formulation. Created in BioRender.CC BY · PubMed Central

Verification

Claims the paper makes

63 Valid · 10 Not valid · 85 Not checked · 51 Own results and interpretations

60 more claims · 17 with their cited sources checked

Create a free account to see all 209 claims and to verify the 41 references still open.

See all claims — free account
  • It may state two separate claims as one. 103
  • Probably not a substantial claim. 64
  • The quote only partly states this claim. 2

Create a free account to see these claims.

Citations

Cites

Show all 372 references

Research works printed but not linked: 2

  1. Ribas, 2002, Infection and disease caused by the human T cell lymphotropic viruses type I and II in Brazil, Rev. Soc. Bras. Med. Trop., 35, 499
  2. Cruz, 2012, Chronic rhinitis in HTLV-1 carriers: A histopathologic study, Braz. J. Otorhinolaryngol., 78, 35

Cited by

See all 22

Metadata

Authors
Wang, T. T., Hirons, A., Doerflinger, M., Morris, K. V., Ledger, S., Purcell, D. F. J., Kelleher, A. D., & Ahlenstiel, C. L.
Affiliations
  • UNSW Sydney (AU)
  • The University of Melbourne (AU)
  • Queensland University of Technology (AU)
Corresponding author
Ahlenstiel, Chantelle L.
Venue
Viruses
Publisher
MDPI AG
Published
2024-10-15
Volume
16
Issue
10
Pages
1616
ISSN
1999-4915 (ISSN-L)
OpenAlex
W4403429851
Cited by
22
References
372
Citations by year
2026: 9 · 2025: 12 · 2024: 1
FWCI
0.97
Type
journal article
Language
en
Open access
Locations
  • Viruses (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by)
Funders
  • an Australian Government Research Training Program Scholarship (APP1149990, GNT2004670, R01 1R01MH134389-01 NIMH)
  • an NHMRC programme grant (APP1149990, GNT2004670, R01 1R01MH134389-01 NIMH)
  • a UNSW Rapid Response Research grant (APP1149990, GNT2004670, R01 1R01MH134389-01 NIMH)
  • the NSW RNA Production Research Network (APP1149990, GNT2004670, R01 1R01MH134389-01 NIMH)
  • a philanthropic grant to the Immunotherapy Research Fund at the Kirby Institute (APP1149990, GNT2004670, R01 1R01MH134389-01 NIMH)
  • the Australian NHMRC Ideas grant (APP1149990, GNT2004670, R01 1R01MH134389-01 NIMH)
  • Australian Centre for HIV and Hepatitis Virology Research (ACH4) Project Grants (APP1149990, GNT2004670, R01 1R01MH134389-01 NIMH)
  • the ACH4 and the Phyllis Connor Memorial Trust (APP1149990, GNT2004670, R01 1R01MH134389-01 NIMH)
  • NIH (APP1149990, GNT2004670, R01 1R01MH134389-01 NIMH)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and Retrovirus Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
Keywords
HTLV-1, antiviral agents, gene therapy, adult T-cell leukemia/lymphoma, tropical spastic paraparesis, retroviral infection, CD4+ T cells, HIV-1, vaccine development, animal models, oncogenic retroviruses
MeSH terms
Animals, Antiviral Agents, Humans, Viral Vaccines, Human T-lymphotropic virus 1, Leukemia-Lymphoma, Adult T-Cell, HTLV-I Infections

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Current State of Therapeutics for HTLV-1. https://app.cochat.ai/papers/10.3390/v16101616
The paper
Wang, T. T., Hirons, A., Doerflinger, M., Morris, K. V., Ledger, S., Purcell, D. F. J., Kelleher, A. D., & Ahlenstiel, C. L. (2024). Current State of Therapeutics for HTLV-1. Viruses. https://doi.org/10.3390/v16101616

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.